Reduced levels of IGF-I mediate differential protection of normal and cancer cells in response to fasting and improve chemotherapeutic index

Cancer Research

Volumn 70, Issue 4, 2010, Pages 1564-1572

  Lee, Changhan ^a   Safdie, Fernando M ^a   Raffaghello, Lizzia ^c   Wei, Min ^a   Madia, Federica ^a   Parrella, Edoardo ^a   Hwang, David ^b   Cohen, Pinchas ^b   Bianchi, Giovanna ^c   Longo, Valter D ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c G GASLINI INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DNA; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; SOMATOMEDIN C;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CANCER CELL; CARCINOGENESIS; CELL PROTECTION; CHEMOPROPHYLAXIS; CHEMOTHERAPY; CONTROLLED STUDY; DNA DAMAGE; DRUG TOXICITY; FIBROBLAST; GLIA; GLIOMA CELL; MELANOMA; METASTASIS; MOUSE; MOUSE EMBRYO; NONHUMAN; PRIORITY JOURNAL; PROTO ONCOGENE; SIGNAL TRANSDUCTION; STARVATION; SURVIVAL TIME;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; CYTOPROTECTION; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FASTING; GROWTH HORMONE; HEALTH STATUS INDICATORS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; INSULIN-LIKE GROWTH FACTOR I; MELANOMA, EXPERIMENTAL; MICE; MICE, KNOCKOUT; NEOPLASMS; STARVATION; STRESS, PHYSIOLOGICAL; TREATMENT OUTCOME;

EID: 76749169812     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-3228     Document Type: Article

References (52)

1. Links M, Lewis C. Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy. Drugs 1999;57:293-308.
2. Raffaghello L, Lee C, Safdie FM, et al. Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy. Proc Natl Acad Sci U S A 2008;105: 8215-20.
3. Longo VD, Finch CE. Evolutionary medicine: from dwarf model systems to healthy centenarians. Science 2003;299:1342-6.
4. Kirkwood TB, Shanley DP. Food restriction, evolution and ageing. Mech Ageing Dev 2005;126:1011-6.
5. Shanley DP, Kirkwood TB. Calorie restriction and aging: a life-history analysis. Evolution 2000;54:740-50.
6. Bartke A. Minireview: role of the growth hormone/insulin-like growth factor system in mammalian aging. Endocrinology 2005; 146:3718-23.
7. Thissen JP, Underwood LE, Ketelslegers JM. Regulation of insulinlike growth factor-I in starvation and injury. Nutr Rev 1999;57:167-76.
8. Merimee TJ, Zapf J, Froesch ER. Insulin-like growth factors in the fed and fasted states. J Clin Endocrinol Metab 1982;55:999-1002.
9. Holzenberger M, Dupont J, Ducos B, et al. IGF-1 receptor regulates life span and resistance to oxidative stress in mice. Nature 2003;421: 182-7.
10. Murakami S. Stress resistance in long-lived mouse models. Exp Gerontol 2006;41:1014-9.
11. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100: 57-70.
12. Xie L, Jiang Y, Ouyang P, et al. Effects of dietary calorie restriction or exercise on the PI3K and Ras signaling pathways in the skin of mice. J Biol Chem 2007;282:28025-35.
13. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004;10:789-99.
14. Anzo M, Cobb LJ, Hwang DL, et al. Targeted deletion of hepatic Igf1 in TRAMP mice leads to dramatic alterations in the circulating insulin-like growth factor axis but does not reduce tumor progression. Cancer Res 2008;68:3342-9.
15. Yakar S, Liu JL, Stannard B, et al. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci U S A 1999;96:7324-9.
16. Craft N, Bruhn KW, Nguyen BD, et al. Bioluminescent imaging of melanoma in live mice. J Invest Dermatol 2005;125:159-65.
17. Cotterill AM, Holly JM, Wass JA. The regulation of insulin-like growth factor binding protein (IGFBP)-1 during prolonged fasting. Clin Endocrinol (Oxf) 1993;39:357-62.
18. Katz LE, Satin-Smith MS, Collett-Solberg P, Baker L, Stanley CA, Cohen P. Dual regulation of insulin-like growth factor binding protein-1 levels by insulin and cortisol during fasting. J Clin Endocrinol Metab 1998;83:4426-30.
19. Frystyk J, Delhanty PJ, Skjaerbaek C, Baxter RC. Changes in the circulating IGF system during short-term fasting and refeeding in rats. Am J Physiol 1999;277:E245-52.
20. Murphy LJ. Overexpression of insulin-like growth factor binding protein-1 in transgenic mice. Pediatr Nephrol 2000;14:567-71.
21. Norrelund H, Frystyk J, Jorgensen JO, et al. The effect of growth hormone on the insulin-like growth factor system during fasting. J Clin Endocrinol Metab 2003;88:3292-8.
22. Zeman SM, Phillips DR, Crothers DM. Characterization of covalent Adriamycin-DNA adducts. Proc Natl Acad Sci U S A 1998;95: 11561-5.
23. Brown-Borg HM, Rakoczy SG, Romanick MA, Kennedy MA. Effects of growth hormone and insulin-like growth factor-1 on hepatocyte antioxidative enzymes. Exp Biol Med 2002;227:94-104.
24. Suh Y, Atzmon G, Cho MO, et al. Functionally significant insulin-like growth factor I receptor mutations in centenarians. Proc Natl Acad Sci U S A 2008;105:3438-42.
25. Yan L, Vatner DE, O'Connor JP, et al. Type 5 adenylyl cyclase disruption increases longevity and protects against stress. Cell 2007; 130:247-58.
26. de Jonge ME, Huitema AD, Rodenhuis S, Beijnen JH. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 2005;44: 1135-64.
27. Manetta J, Brun JF, Maimoun L, Callis A, Prefaut C, Mercier J. Effect of training on the GH/IGF-I axis during exercise in middle-aged men: relationship to glucose homeostasis. Am J Physiol Endocrinol Metab 2002;283:E929-36.
28. Drakas R, Tu X, Baserga R. Control of cell size through phosphorylation of upstream binding factor 1 by nuclear phosphatidylinositol 3-kinase. Proc Natl Acad Sci U S A 2004;101:9272-6.
29. Longo VD, Lieber MR, Vijg J. Turning anti-ageing genes against cancer. Nat Rev Mol Cell Biol 2008;9:903-10.
30. Baserga R. The IGF-I receptor in cancer research. Exp Cell Res 1999; 253:1-6.
31. Wei M, Fabrizio P, Hu J, et al. Life span extension by calorie restriction depends on Rim15 and transcription factors downstream of Ras/ PKA, Tor, and Sch9. PLoS Genet 2008;4:e13.
32. Madia F, Gattazzo C, Wei M, et al. Longevity mutation in SCH9 prevents recombination errors and premature genomic instability in a Werner/Bloom model system. J Cell Biol 2008;180:67-81.
33. Madia F, Gattazzo C, Fabrizio P, Longo VD. A simple model system for age-dependent DNA damage and cancer. Mech Ageing Dev 2007;128:45-9.
34. Ishikawa M, Mizobuchi M, Takahashi H, Bando H, Saito S. Somatostatin release as measured by in vivo microdialysis: circadian variation and effect of prolonged food deprivation. Brain Res 1997;749: 226-31.
35. Hejna M, Schmidinger M, Raderer M. The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing? Ann Oncol 2002;13:653-68.
36. Susini C, Buscail L. Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol 2006;17:1733-42.
37. Zalatnai A, Schally AV. Treatment of N-nitrosobis(2-oxopropyl) amine-induced pancreatic cancer in Syrian golden hamsters with D-Trp-6-LH-RH and somatostatin analogue RC-160 microcapsules. Cancer Res 1989;49:1810-5.
38. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004;4:505-18.
39. Hande KR. Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer 1998;34:1514-21.
40. Lode HN, Xiang R, Varki NM, Dolman CS, Gillies SD, Reisfeld RA. Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow. J Natl Cancer Inst 1997;89: 1586-94.
41. Migliaccio E, Giorgio M, Mele S, et al. The p66shc adaptor protein controls oxidative stress response and life span in mammals. Nature 1999;402:309-13.
42. Patel AC, Nunez NP, Perkins SN, Barrett JC, Hursting SD. Effects of energy balance on cancer in genetically altered mice. J Nutr 2004; 134:3394-8S.
43. Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003;3:330-8.
44. Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007;28:20-47.
45. Keyomarsi K, Pardee AB. Selective protection of normal proliferating cells against the toxic effects of chemotherapeutic agents. Prog Cell Cycle Res 2003;5:527-32.
46. Blagosklonny MV, Pardee AB. Exploiting cancer cell cycling for selective protection of normal cells. Cancer Res 2001;61:4301-5.
47. Blagosklonny MV, Darzynkiewicz Z. Cyclotherapy: protection of normal cells and unshielding of cancer cells. Cell Cycle 2002;1: 375-82.
48. Li Y, Xu W, McBurney MW, Longo VD. SirT1 Inhibition Reduces IGF-I/IRS-2/Ras/ERK1/2 Signaling and Protects Neurons. Cell Metab 2008;8:38-48.
49. Blagosklonny MV, Bishop PC, Robey R, Fojo T, Bates SE. Loss of cell cycle control allows selective microtubule-active drug-induced Bcl-2 phosphorylation and cytotoxicity in autonomous cancer cells. Cancer Res 2000;60:3425-8.
50. Blagosklonny MV, Robey R, Bates S, Fojo T. Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs. J Clin Invest 2000;105: 533-9.
51. Demidenko ZN, Halicka D, Kunicki J, McCubrey JA, Darzynkiewicz Z, Blagosklonny MV. Selective killing of Adriamycin-resistant (G2 checkpoint-deficient and MRP1-expressing) cancer cells by docetaxel. Cancer Res 2005;65:4401-7.
52. Tao Y, Pinzi V, Bourhis J, Deutsch E. Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway-therapeutic perspectives in cancer. Nat Clin Pract Oncol 2007;4:591-602.